MasterCard Inc vs Medtronic PLC — how do they compare? MasterCard Inc trades at $561.9 (market cap $493.34B), while Medtronic PLC trades at $90.58 (market cap $114.45B). The key difference: MasterCard Inc is far larger — about 4.3× Medtronic PLC's market cap, and Medtronic PLC pays the higher dividend (3.22%). Which is the better fit depends on your goals.
| MA | MDT | |
|---|---|---|
Market Cap | $493.34B | $114.45B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $598.96 | $105.35 |
52-Week Low | $471.55 | $73.75 |
Enterprise Value | $506.38B | $133.19B |
Dividend Yield | 0.62% | 3.22% |
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $563.17, up 0.04% on the day, with a bullish technical signal supported by moving averages and strong institutional buying interest. The company continues to deliver robust financial performance, with Q2 2026 EPS of $5.04 beating estimates of $4.77, marking the third consecutive quarterly beat. Revenue growth remains strong, rising from $22.2B in 2022 to $32.8B in 2025, while maintaining net income margins above 45%. Recent news highlights Mastercard's expansion into AI-driven payments and initiatives to connect underbanked populations.
The outlook for MA remains positive given its consistent earnings beats, high profitability, and dominant market position. However, investors should monitor competitive threats from emerging payment technologies like stablecoins and regulatory scrutiny. With 79% analyst buy ratings and a consensus price target of $660.85, Wall Street sees approximately 17% upside potential from current levels.
Medtronic (MDT) trades at $87.16, up 1.44% today, with a bullish technical signal and consistent earnings beats. The company reported Q1 2026 EPS of $1.55, exceeding expectations, and maintains solid fundamentals with a 13.2% net income margin and $33.54B in revenue for 2025. Recent news highlights growth in cardiac ablation and the Hugo robotic platform, with management guiding for 11.75% organic revenue growth in Q1 2027.
The outlook is positive, supported by analyst consensus of a $98.75 price target and 60% buy ratings. Key opportunities include dividend stability and innovation in medical technology, while risks involve rising debt levels and competitive pressures. The stock's current valuation at a P/E of 23.37 offers moderate upside if execution continues.
Trailing returns across standard periods
Latest headlines on both assets
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →